Share Prices & Company Research

Market News

11 Mar 2021 | 13:50

Talks between Hikma and GlaxoSmithKline fail to secure a deal

(Sharecast News) - Talks between Hikma Pharmaceutical and drugs giant GlaxoSmithKline have ended, the generics group confirmed on Thursday. Hikma was in discussions to acquire GSK's pharmaceutical and consumer businesses in Egypt along with its pharmaceutical business in Tunisia. The blue chip entered into a non-binding term sheet with GSK in January, but on Thursday it said that the talks had now finished.

In a brief statement, Hikma said: "Both companies have agreed to cease discussions regarding the proposed transaction and, accordingly, Hikma will not be launching a mandatory tender offer process to acquire the shares in GlaxoSmithKline SAE Egypt."

No reason was given for the ending of the talks. However, when it first confirmed the discussions, Hikma said further talks would depend on the result of its due diligence process. It also confirmed any potential transaction would be subject to a number of conditions and there was no guarantee a deal would be struck.

UK-headquartered Hikma, which was founded in Jordon by Samih Darwazah in 1978, is one of the world's biggest generics groups. It floated in 2005 but the Darwazah family remain its biggest shareholder with a 26% stake.

As at 1415 GMT, shares in Hikma were down 1% at 2,246.0p, while GSK was also trading 1% lower, at 1,252.0p.

No financial terms were associated with the potential transaction.
Get in touch today
Join Redmayne Bentley
Talk to us now about opening a new account or transferring your account from another provider
0113 243 6941
Get in touch today
Contact your local office
Contact your local office to find out more
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
Continuing our Personal Service: View our Latest COVID-19 Update: 30th April 2021
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.